A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)

Document Type

Conference Proceeding

Publication Date

10-20-2023

Publication Title

Annals of Oncology

Abstract

ESMO Congress 2023, October 20 - 24, 2023, Madrid, Spain

First Page

S1204

Last Page

S1205

Volume

34

Issue

Supplement 2

Comments

Abstract #2367P

Share

COinS